- Home
- EGY vs YMAB Comparison
EGY vs YMAB Comparison
Compare EGY & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- YMAB
- Stock Information
- Founded
- EGY 1985
- YMAB 2015
- Country
- EGY United States
- YMAB United States
- Employees
- EGY N/A
- YMAB N/A
- Industry
- EGY Oil & Gas Production
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- YMAB Health Care
- Exchange
- EGY Nasdaq
- YMAB Nasdaq
- Market Cap
- EGY 497.4M
- YMAB 482.4M
- IPO Year
- EGY N/A
- YMAB 2018
- Fundamental
- Price
- EGY $4.66
- YMAB $9.62
- Analyst Decision
- EGY Strong Buy
- YMAB Strong Buy
- Analyst Count
- EGY 1
- YMAB 10
- Target Price
- EGY $8.00
- YMAB $21.00
- AVG Volume (30 Days)
- EGY 1.0M
- YMAB 243.1K
- Earning Date
- EGY 11-11-2024
- YMAB 11-08-2024
- Dividend Yield
- EGY 5.31%
- YMAB N/A
- EPS Growth
- EGY 170.05
- YMAB N/A
- EPS
- EGY 0.86
- YMAB N/A
- Revenue
- EGY $506,421,000.00
- YMAB $84,553,000.00
- Revenue This Year
- EGY $0.48
- YMAB $6.46
- Revenue Next Year
- EGY N/A
- YMAB $20.68
- P/E Ratio
- EGY $5.48
- YMAB N/A
- Revenue Growth
- EGY 25.82
- YMAB N/A
- 52 Week Low
- EGY $4.03
- YMAB $6.09
- 52 Week High
- EGY $7.51
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- EGY 30.56
- YMAB 32.94
- Support Level
- EGY $4.58
- YMAB $9.31
- Resistance Level
- EGY $5.08
- YMAB $11.10
- Average True Range (ATR)
- EGY 0.18
- YMAB 0.79
- MACD
- EGY -0.01
- YMAB -0.00
- Stochastic Oscillator
- EGY 11.19
- YMAB 7.27
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea and Corporate and Other. The company generates maximum revenue from the Gabon segment.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.